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Abstract
Haemolytic Uraemic Syndrome (HUS) is an acquired disorder affecting 
mainly infants and children. The triad of this clinical syndrome is defined by: 
1) Thrombotic or Microangiopathic Haemolytic Anaemia with schistocytes 2) 
Thrombocytopenia and 3) Acute Renal Failure (ARF) which can develop into 
Chronic Kidney Disease (CKD). The aim of this article is to provide an editorial/
commentary on the Clinical Medicine versus Clinical Anatomy of HUS. 
HUS is the most common cause of Acute Renal Failure (ARF) in children 
with an equal sex incidence [1]. The annual incidence of VTEC infection varies 
geographically; it can range from 1 to 30 cases per 100,000 in industrialized 
countries. It is a rare syndrome post-puberty but it is also closely related to 
Thrombotic Thrombocytopenia (TTP) which is common in adults. The annual 
incidence of the Verocytotoxin-producing Esherichia Coli (VTEC) infection 
varies geographically from year to year, ranging from 1-30 cases per 100,000 
in industrialized countries and is associated with HUS. HUS occurs in sporadic 
cases epidemics; between 1st January [2] and 31st December [2] in England, 
a total of 3717 cases were reported with evidence of Shiga Toxin-Producing E. 
Coli (STEC) infection; sometimes following outbreaks. In Hamburg [3], there 
was an outbreak with more than 900 cases. The disease has seasonal variation, 
being more common in the warmer months in children. 
Renal histopathology is characterized by abnormal morphology applicable 
to afferent arterioles and glomeruli. The glomeruli show evidence of global 
sclerosis and glomerular thrombotic microangiopathy endothelial cell swelling; 
capillary wall thickening and glomerular basement membranes also evident. 
Interstitial fibro edematous change and tubular atrophy are marked. Arterial, 
arteriolar and capillary lumina are narrow with obstruction and intimal thickening. 
The nature of vascular involvement in the kidneys supports the hypothesis that 
HUS is mediated by systemic toxemia and endothelial cells are the primary 
target cells owing to action of Verocytotoxin. Histopathological findings provide 
clues not only to the diagnosis but also in the support of prognosis. Diffuse 
tubular interstitial change and global sclerosis indicate the degree of blood flow 
obstruction and prognosis. Renal blood flow obstruction caused by diffused 
arterial and arteriolar luminal stenosis may lead to irreversible changes in renal 
pathology
Keywords: Haemolytic Uraemic Syndrome (HUS); Clinical medicine; 
Clinical anatomy; Chronic kidney disease; Acute renal failure; Haematology
micro-organisms causing diarrhoea, (and those thus leading to HUS 
and/ or HUS related symptoms) may become more important in 
future health consultations [3].
E.coli 0157:H7 is the most commonly notified VT-producing 
organism in the UK and France. Clinical manifestations may vary 
from an asymptomatic infection to bloody diarrhoea, haemorrhagic 
colitis and HUS. Verotoxin Enterococcal (VTEC)-associated HUS 
was seen in up to 20% of patients in recent outbreaks, mainly affecting 
children [5]. Table 1 summarizes the defining classification of HUS 
and (Table 2) summarizes features of HUS, respectively.
HUS epidemiology
HUS is the most common cause of Acute Renal Failure (ARF) 
in children with an equal sex incidence [1]. The annual incidence of 
Introduction
Haemolytic Uraemic Syndrome (HUS) occurs due to Shiga-
like toxin activity via aberrant complement activation. HUS is 
typically classified into two primary types: 1) HUS due to infections, 
often associated with diarrohea (D+HUS, Shiga toxin-producing 
Escherichia Coli-HUS), with the rare exception of HUS due to a 
severe disseminated infection caused by Streptococcus; 2) HUS 
related to complement, such HUS is also known as “atypical HUS” 
and is not diarrohea associated (D-HUS, aHUS) [4]. Clinical features 
include proteinuria, renal impairment and history of E. coli diarrohea 
(hallmark of typical HUS). Encephalopathy is rare but can cause 
death. HUS is seen increasingly following outbreaks of infection with 
Verotoxin (VT)-producing organisms. It represents a growing public 
health problem and data suggest that more awareness of specific 
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VTEC infection varies geographically; it can range from 1 to 30 cases 
per 100,000 in industrialized countries. There is seasonal variation, 
thus being more common in warmer months. It is more common in 
those under 5-years.
Between 1st January [6] and 31st December [6] in England, a total 
of 3717 cases were reported with evidence of Shiga Toxin-producing 
E. Coli (STEC) infection, and the crude incidence of STEC infection 
was 1•80/100 000 person-years. Incidence was highest in children 
aged 1-4 years (7•63/100 000 person-years) [2].
HUS diarrohea association
Most common cause of HUS and intrinsic ARF in paediatrics in 
the UK, France and USA industrialized countries is diarrhoea. There 
are no specific therapies to treat the diarrohea. Mortality is as high as 
8.5 % and up to 30 % of survivors may develop further Glomerular 
Filtration Rate (GFR) impairment or albuminuria [6]. 
Use of anti-motility drugs may increase the risk of developing 
HUS and it is a rare syndrome post-puberty [1]. Atypical HUS 
(aHUS) can be inherited or acquired and does not appear to vary by 
race, gender or geographic area. Data on the prevalence of aHUS is 
limited [7,8] (Table 3). 
HUS and laboratory tests/ investigations
Haemolysis and red cell fragmentation are usually evident at 
presentation, although this rarely develops later in the disease even 
after platelet count improvement (Table 4). Coagulation studies 
are usually normal with mildly raised D-dimer titres in contrast 
to Disseminated Intravascular Coagulation (DIC) [9]. The Von-
Willebrand Factor (VWF) levels are usually markedly raised during 
acute illness while analysis may/ may not show ultra-large multimers 
[10]. Poor prognostic features at presentation include a high 
neutrophil count [11]. Severe thrombocytopenia is uncommon but 
prolonged thrombocytopenia for more than 10 days is associated 
with long-term renal picture. Factor VIII levels do not correlate 
with clinical outcome [12]. Table 5 summarizes laboratory tests/ 
investigations according to Haematology specialty. Figure 1 depicts 
HUS red cell morphology under microscopy.
Prognosis and treatment
Treatment is by supportive measure, and the main treatments 
are either Haemodialysis (HD) or Peritoneal Dialysis (PD) because 
of the ARF. The prognosis is dependent upon the aetiology and renal 
function; there is a poor prognosis if patient requires HD or PD more 
than 7 days, but good prognosis is conceivable with total recovery 
of renal function with no arterial hypertension, and no proteinuria. 




Shiga toxin producing E. coli/ Shigella
Pneumococcal infection
HIV
Other viral or bacterial infections
Atypical
Complement factor abnormality
Factor H deficiency and Factor I deficiency
Miscellaneous
Cumulative Trauma Disorder (CTD), drugs, malignancy
Table 1: Classification of HUS.
HUS - Defining Features
• Renal involvement
• Evidence of coagulopathy –intravascular coagulation in the kidney
• Antipathy - marked fragmentation of red cells
• The disorder is associated with activation of neutrophils
• Typical HUS is secondary to GI infection with Verocytotoxin-producing 
E-coli 0157:H7 (VTEC), less often Shigella
• Complement activation used to attack foreign bodies
• Complement system highly regulated to prevent it from damaging healthy 
tissues/ organs
• Platelet activation, damage to endothelial cells (cells that line the blood 
vessels), white blood cell activation causing haemolysis
• Thrombotic Microangiopathy (TMA) – formation of blood clots in small 
vessels throughout the body and over time, causing multiple organ 
damage
Table adopted from (Blaser 2004; Licht et al. 2009)
Table 2: Defining features of HUS.
HUS - Signs
• Patients present with anaemia
• Petechiae, purpura, and fever are common
• GI bleeding is often found and a bloody diarrohea
• GI disease may be severe with haemorrhagic colitis, toxic megacolon, 
rectal prolapse, and bowel necrosis
• Neurological symptoms
• Cardiac involvement may lead to Congestive Heart Failure (CHF) and 
arrhythmias
• Microinfarcts in the pancreas (pancreatitis) or, rarely, Insulin Dependent 
Diabetes Mellitus (IDDM)
Table adopted from (Licht et al., 2009)
Table 3: HUS signs.
HUS - Symptoms
• The kidneys are swollen and pale
• Many flea-bite hemorrhages are on the surface
• GI involvement may lead to symptoms of an acute abdomen, with 
occasional perforation
• Hypertension
• Anuria – Oliguria, depending on overall GFR/ renal function
Table adopted from (Licht et al., 2009)
Table 4: HUS symptoms.
HUS - Haematology
Full Blood Count (FBC) highlights an anaemic picture on presentation
Coagulation highlights APTT and PT are both normal - suggests sepsis rather 
than HUS/TTP
Platelet and fibrin micro-thrombi is evident within the renal microvasculature
Thrombocytopenia is universal at some point in the illness
Haematinics highlight there is variability in Iron titres
Direct Coombes Test is Negative
Plasma Haptoglobin levels is decreased owing to Red Blood Cell (RBC) 
breakdown/ degradation
Raised Fraction Degradation Products (FDPs)
There is a slightly elevated D-Dimer
There may be  microcytosis
Red cell enzymes and osmotic fragility are normal
Reticulocyte count is elevated
Table adapted from (Taylor et al., 1999; Taylor 2001a; Taylor 2001b; Taylor et 
al., 2004)
Table 5: HUS – Haematology.
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exchange, but efficacy and long-term use is not advisable [13-15]. 
Major neurological dysfunction occurs in a third of patients in 
atypical HUS and less than 10% in typical HUS; is associated with 
a poor prognosis [7]. There should be supportive information made 
available for the patient and parent or career/guardian. Eculizumab 
is a monoclonal antibody that binds to C5 to prevent the formation 
of C5a and the membrane attack complex [7,8]. This treatment has 
become popular and can be helpful for patients who may have extra 
renal involvement such as that seen in typical HUS. Its efficacy and 
safety in the treatment of aHUS has been highlighted recently [7,8].
Management
Either HD or PD treatments is essential when renal function 
is altered. It is crucial to control hypertension, thus preventing 
Figure 1: HUS red cell morphology under microscopy. RBC fragmentation 
with obvious schistocytes/ helmet cells. Note decrease in platelets which is a 
typical picture in HUS patients. Schistocytes are irregularly shaped fragments 
with two pointed ends without central pallor (Barcellini & Fattizzo 2015). 
Slide taken from (http://emedicine.medscape.com/article/779218-workup) 
(accessed December 2016).
Figure 2: Histological Stains of a Kidney Biopsy Specimen – Day 37 following 
Eculizumab Treatment characteristic of a HUS. (A) Almost all glomeruli give 
evidence of global sclerosis or collapse (Periodic Acid Schiff stain [PAS]; 
×100). (B) Endothelial swelling is conspicuous and glomerular basement 
membranes are focally duplicated (Periodic Acid Methenamine silver stain 
[PAM]; ×1000). (C) Interstitial fibroedematous change and tubular atrophy 
are marked (Haematoxylin and Eosin stain [H&E]; ×200). (D, E) Arterial and 
arteriolar lumina stenosed or obstructed with intimal thickening (Elastica van 
Gieson stain [EVG]; ×1000). (F) Mononuclear cells infiltrated into intima of 
arteries (PASX1000). These findings are helpful demonstrating the diagnosis 
of TMA diagnosis (Slide stain taken from Okuda et al. 2015).
any longer term complications (Figures 2 and 3). RBC transfusion 
in children is common owing to anaemia [13-15]. Fraction Frozen 
Plasma (FFP) has been administered in adults [8]. 
Research perspectives
Haemoglobin (Hb) is the most direct indicator of clinical severity 
in haemolytic diseases. Its level may be close to normal values in mild 
forms (Hb >10 g/dL) or reduced in moderate (Hb 8–10 g/dL), severe 
(Hb 6–8 g/dL), and very severe (Hb 6 g/dL) forms (WHO 1989). In 
a differential diagnosis, an acute onset is more frequently observed 
in RBC enzymopathies involving the Pentose Phosphate (PP) shunt 
Figure 3: HUS - fibrin histological stain. Fibrin histological stain highlighting 
platelet-fibrin thrombi (red) in the glomerular capillaries, characteristic 
of HUS/microangiopathic disorder, (taken from http://slideplayer.com/
slide/11018533/) (accessed December 2016). 
HUS – Key Morphological Features
Peripheral blood smear depicts striking red cell fragmentation
Findings of microangiopathic haemolytic anaemia
Deformed, irregular or helmet-shaped RBCs – schistocytes
Thrombocytopenia (counts of 50 x 109/l) or less
Neutrophil may be quite marked – it is a marker of adverse prognosis
Polychromasia (greyish tinge) may be marked
Bone Marrow is cellular – response to haemolysis/ red cell breakdown
Table adapted from (Taylor et al., 1999; Taylor 2001a; Taylor 2001b; Taylor et 
al., 2004)
Table 6: HUS key haematology morphological features.
HUS - Chemistry
Urea, Creatinine and Electrolytes demonstrate abnormally high results
Urine, if present, may contain protein and RBCs
Liver Function Test (LFTS) can be normal
Urine dipstick can show some protein leaking (24hr urine collection needed to 
quantify)
Electrophoresis can be helpful and important to establish extent of protein 
leaking
Blood Urea Nitrogen (BUN) is markedly elevated
HUS - Microbiology
Cultured species of E-coli is performed
Mainly looking for group Enterohaemarrohagic E-Coli (EHEC)
(Table adapted from Taylor et al., 1999; Taylor 2001a; Taylor 2001b; Taylor et 
al., 2004)
Table 7: HUS– chemistry/ microbiology.
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(e.g. glucose-6-phosphate-dehydrogenase, G6PD deficit) and in 
autoimmune haemolytic forms involving complement activation 
Autoimmune Haemolytic Anaemia (AIHA) caused by warm IgM, 
warm IgG + C, mixed, and Cold Agglutin Disease (CAD) (with 
thermal range close to physiological temperatures) and in Paroxysmal 
Nocturnal Haemoglobinuria (PNH) (Tables 6,7 and 8).
Summary
Clinical medicine
• Bloody’ diarrohea still most crucial element to be aware of 
in young patients
• Renal Function over time must be monitored
• Haemolytic parameters may be differently altered in 
the various conditions thus helping the differential diagnosis and 
coagulation must be monitored
• LDH is useful in evaluating response to treatment, as its 
level decreases along with the reduction of the haemolytic rate 
• Polynucleosis is a factor of poor prognosis 
Clinical anatomy/histopathology
• Glomerulus: hyalinized, thickened and sometimes split 
capillary walls due to endothelial swelling
• Tubules: atrophied and contains hyalinised casts
• Interstitium: fibrosed with lymphocystic infiltration
• Vessels: arterial and arteriolar sclerosis, intimal hyperplasia 
and fibrinoid necrosis with large deposits of fibrin-related materials 
in the capillary lumen. They are often occluded by thrombi.
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HUS – Key Histopathological Features
Afferent arterioles and glomeruli inflammation
Ischaemic necrosis in renal cortex may occur from intravascular coagulation
Glomerular thrombosis and sclerosis
Hypercellularity
Sclerotic tuft
Fibrinous necrosis in places and some tubule-interstitial compartments show 
atrophic changes with infiltration of the inflammatory cells
Endocapillary swelling with diffuse arteriolar and arterial luminal stenosis due to 
the thickness and sclerotic changes of the media and intima
Renal Scarring
Table adapted from (Taylor et al., 1999; Taylor 2001a; Taylor 2001b; Taylor et 
al., 2004; Okuda et al., 2016)
Table 8: HUS key anatomical/histopathological features. References
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